On July 20, 2021 Alexion reported with the exciting news that we have been acquired by AstraZeneca, a global, science-led biopharmaceutical company (Press release, Alexion, JUL 20, 2021, View Source [SID1234585003]). This development also marks the creation of Alexion, AstraZeneca Rare Disease.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alexion and AstraZeneca share a dedication to science, to innovation, and to delivering life-changing medicines to the patients who need them most. Together, we have the opportunity to add more value for more patients worldwide across a full-spectrum of care.
Alexion’s innovative complement-biology platforms and robust pipeline place AstraZeneca in a strong position for enhancing its scientific presence in the immunology sector. Most importantly, together we will be better positioned to ensure the ongoing discovery and development of medicines for rare diseases and devastating conditions.
Pascal Soriot, Chief Executive Officer of AstraZeneca, said: "Today we welcome our new colleagues from Alexion to AstraZeneca and begin a new chapter that will augment our growth for years to come. Our sustained R&D investment in oncology, cardiovascular and renal, as well as respiratory and immunology, has powered AstraZeneca’s transformation and now we add rare diseases, where fewer approved treatment options exist."
Marc Dunoyer, incoming Chief Executive Officer of Alexion and Chief Financial Officer, AstraZeneca said: "I am delighted to be working alongside my new colleagues at Alexion where we will continue to discover, develop and deliver medicines that change the lives of people suffering from rare diseases. We look forward to also applying Alexion’s complement-biology platform across areas of AstraZeneca’s broader early stage pipeline and, significantly, to the extraordinary opportunity to extend existing and future rare disease medicines to patients in many countries where AstraZeneca already has a strong presence."